Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | EYA2 | O00167 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL4385387 | 1.00 | GSR (0.60) | GSRTDP1EYA2APPACE | |
| Edetic Acid SCHEMBL28302111 | 0.93 | GSR (0.67) | GSRTDP1EYA2APPACE | |
| Pentetic Acid SCHEMBL7885826 | 0.93 | GSR (0.67) | GSRTDP1EYA2APPACE | |
| Edetic Acid SCHEMBL30301418 | 0.93 | GSR (0.67) | GSRTDP1EYA2APPACE | |
| Nitrilotriacetic Acid SCHEMBL4200594 | 0.87 | GSR (0.74) | GSRCYP2C19TSHRBLMBHMT | |
| SCHEMBL10088295 | 0.87 | NOS2 (0.51) | GSRTDP1EYA2APPACE | |
| SCHEMBL5613110 | 0.86 | TDP1 (0.50) | GSRTDP1EYA2APPACE | |
| SCHEMBL2305699 | 0.85 | GSR (0.53) | GSRTDP1EYA2APPACE | |
| SCHEMBL158633 | 0.85 | GSR (0.53) | GSRTDP1EYA2APPACE | |
| SCHEMBL10088294 | 0.84 | GSR (0.52) | GSRTDP1EYA2APPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10175233-B2 | Biomarkers for cardiovascular diseases and methods using the same | METABOLON, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20160178620-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. | 2016-06-23 | — | — | US | disclosed |
| US-9250225-B2 | Biomarkers for insulin resistance and methods using the same | METABOLON, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150005195-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8809008-B2 | Biomarkers for impaired glucose tolerance and methods using the same | METABOLON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130338031-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. | 2013-12-19 | — | — | US | disclosed |
| EP-2164977-B1 | BIOMARKERS FOR PRE-DIABETES AND METHODS USING THE SAME | METABOLON INC (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8546098-B2 | Biomarkers for monitoring insulin resistance and methods using the same | METABOLON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120208215-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8187830-B2 | Method for determining insulin sensitivity with biomarkers | METABOLON, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090155826-A1 | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same | METABOLON, INC. (US) | 2009-06-18 | — | — | US | disclosed |